Essential Facts About BioNTech SE

Shares of BioNTech SE have moved -2.1% today, and are now trading at a price of $96.95. In contrast, the S&P 500 index saw a 1.0% change. Today's trading volume is 1,245,252 compared to the stock's average volume of 672,185.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Based in Mainz, Germany the company has 6,133 full time employees and a market cap of $23,363,979,264.

The company is now trading -16.61% away from its average analyst target price of $116.26 per share. The 17 analysts following the stock have set target prices ranging from $90.26 to $171.49, and on average give BioNTech SE a rating of buy.

Over the last 12 months BNTX shares have declined by -7.1%, which represents a difference of -33.2% when compared to the S&P 500. The stock's 52 week high is $125.83 per share and its 52 week low is $85.21. Based on BioNTech SE's average net margin growth of 8.6% over the last 5 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 3,819,000 930,300 24 -56.36
2022 17,310,600 9,434,400 55 1.85
2021 18,976,700 10,292,500 54 1700.0
2020 482,300 15,200 3 101.82
2019 108,600 -179,200 -165 -334.21
2018 127,575 -48,262 -38
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS